Becton, Dickinson and Company $BDX Shares Sold by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 35.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,749 shares of the medical instruments supplier’s stock after selling 4,320 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in Becton, Dickinson and Company were worth $1,504,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Becton, Dickinson and Company by 13.0% in the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after buying an additional 4,223,149 shares during the period. State Street Corp grew its position in shares of Becton, Dickinson and Company by 3.4% in the third quarter. State Street Corp now owns 13,872,395 shares of the medical instruments supplier’s stock valued at $2,596,496,000 after purchasing an additional 459,219 shares during the period. First Eagle Investment Management LLC increased its stake in Becton, Dickinson and Company by 16.5% during the 4th quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock worth $2,260,139,000 after buying an additional 1,651,592 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Becton, Dickinson and Company by 3.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 9,486,694 shares of the medical instruments supplier’s stock worth $1,841,083,000 after purchasing an additional 336,110 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in shares of Becton, Dickinson and Company by 9,056.3% in the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock valued at $979,290,000 after buying an additional 5,174,944 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Up 0.2%

Shares of NYSE:BDX opened at $144.50 on Friday. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The stock’s 50-day moving average price is $155.37 and its two-hundred day moving average price is $179.58. The firm has a market cap of $39.81 billion, a price-to-earnings ratio of 36.58, a PEG ratio of 10.21 and a beta of 0.22. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, research analysts forecast that Becton, Dickinson and Company will post 12.61 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

Becton, Dickinson and Company declared that its Board of Directors has approved a stock repurchase program on Tuesday, January 27th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on BDX shares. Piper Sandler reduced their price objective on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Weiss Ratings downgraded shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday. TD Cowen dropped their price objective on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a report on Monday, May 4th. Evercore increased their price objective on Becton, Dickinson and Company from $180.00 to $190.00 in a report on Thursday, May 7th. Finally, JPMorgan Chase & Co. dropped their target price on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a report on Tuesday, February 10th. Seven equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Hold” and a consensus target price of $184.86.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the sale, the director directly owned 36,763 shares in the company, valued at $6,713,291.43. The trade was a 2.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 1,102 shares of company stock valued at $198,909 over the last ninety days. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.